{"id":684380,"date":"2026-03-27T01:00:17","date_gmt":"2026-03-27T01:00:17","guid":{"rendered":"https:\/\/www.europesays.com\/us\/684380\/"},"modified":"2026-03-27T01:00:17","modified_gmt":"2026-03-27T01:00:17","slug":"exclusive-blossom-health-raises-20-million-to-bring-an-ai-copilot-to-psychiatry","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/684380\/","title":{"rendered":"Exclusive: Blossom Health raises $20 million to bring an AI \u2018copilot\u2019 to psychiatry"},"content":{"rendered":"

Blossom Health has raised $20 million in seed and Series A funding to bring an AI \u201ccopilot\u201d for psychiatry to patients nationwide, Fortune has exclusively learned. The announcement comes as venture dollars have largely chased<\/a> more generic AI plays, but as investors have increasingly begun to fund<\/a> AI enabled health tech. The New York\u2013based startup is positioning itself as an AI\u2011native psychiatry platform, arguing that the technology finally makes it possible to scale high\u2011quality mental health care without flooding clinics with more staff.<\/p>\n

The round, led by Headline with participation from Village Global, TA Ventures, Operator Partners, and Correlation Ventures, also adds Headline cofounder Mathias Schilling to the board.\u00a0<\/p>\n

\u201cWe\u2019ve been very intentional and disciplined around capital raising,\u201d founder and CEO John Zhao told Fortune, noting that all of Blossom\u2019s rounds were oversubscribed but that the company \u201ccould raise more, but we choose not to.\u201d Capital, he added, \u201cis both a weapon and a liability.\u201d<\/p>\n

Zhao, who previously worked at two hyperscale startups\u2014Athelas, now a multibillion\u2011dollar<\/a> company, and online insurance marketplace EverQuote, which he helped scale through an IPO\u2014frames Blossom as a chance to build a \u201cgenerational company\u201d in mental health. \u201cAs long as there are human beings, we\u2019re going to need healthcare, and mental health is only a larger and larger component of each person\u2019s holistic health,\u201d he said.<\/p>\n

Blossom\u2019s timing, he sees as a counterpoint to the perception that digital mental health has already been solved by the last wave<\/a> of teletherapy and telehealth platforms. Those platforms, Zhao described as \u201cill\u2011equipped or nonexistent\u201d in the psychiatry space.<\/p>\n

Blossom markets itself as an \u201call\u2011in\u2011one AI copilot\u201d that both augments psychiatrists\u2019 clinical decisions and automates the back office tasks that typically bog down an in\u2011network practice. That means turning what Zhao describes as historically \u201cextremely episodic\u201d care into a continuous relationship driven by AI agents that text patients between visits, help surface warning signs, and tee up information for clinicians. He pointed to a postpartum depression case, where instead of waiting a month until the next visit, Blossom follows up with conversational check\u2011ins on sleep and mood, \u201cjust like texting a therapist,\u201d rather than relying on static questionnaires. In general, most patients on the platform are seen in under 48 hours, oftentimes same-day.\u00a0<\/p>\n

Zhao is blunt that AI in health care will only work if clinicians buy in. \u201cIt starts with listening to clinicians\u2014and not just listening, but involving them in the creation of all our AI products every step of the way,\u201d he said, noting that Blossom\u2019s clinical director and \u201c100\u2011plus clinicians\u201d pilot features before they roll out more broadly.<\/p>\n

He draws a sharp line between clinical tools and support agents, however. \u201cThese are ways we help clinicians treat patients more confidently, accurately, and effectively,\u201d Zhao told Fortune. Everything else\u2014billing, scheduling, dealing with insurers and pharmacies\u2014is handled by agents that replace what he describes as the \u201carmy of people\u201d it used to take to run a clinic.<\/p>\n

Blossom says its tools are already used by hundreds of clinicians treating more than 10,000 patients across multiple states, and it markets in\u2011network coverage with major insurers and average copays around $22. The company pitches itself against a backdrop in which roughly one in four<\/a> U.S. adults experience a mental health condition in a given year, and more than 28 million adults with mental illness receive no treatment at all.<\/p>\n

Zhao\u2019s ambition is to turn Blossom into the \u201cdestination of choice\u201d in psychiatry, analogous to a JPMorgan Chase<\/a> in retail banking, with concrete plans to expand well beyond the nine states it currently serves in the near future, deepen payer relationships, and keep investing in applied AI R&D. \u201cPreviously, scale was something that broke healthcare companies,\u201d Zhao said. \u201cNow we\u2019ve flipped that paradigm on its head. The more we grow, the better we are at helping our doctors and helping our patients.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Blossom Health has raised $20 million in seed and Series A funding to bring an AI \u201ccopilot\u201d for…\n","protected":false},"author":3,"featured_media":684381,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[35],"tags":[210,1141,1142,4500,134394,1968,67,132,68,1594],"class_list":["post-684380","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-health","tag-health-care","tag-healthcare","tag-seed-funding","tag-series-a","tag-start-up","tag-united-states","tag-unitedstates","tag-us","tag-venture-capital"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116298437536327367","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/684380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=684380"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/684380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/684381"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=684380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=684380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=684380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}